{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Appendix 5', 'Excluded Medications/Therapy', 'Excluded medications/therapy are listed in Section 5.2 and Section 6.5. The use of an excluded', 'medication/therapy is a protocol violation and must be recorded in the eCRF.', '68']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Appendix 6', 'Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Definitions:', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming postmenopausal unless', 'permanently sterile (see below).', 'Women in the following categories are not considered WOCBP:', '1. Premenarchal', '2. Premenopausal female with 1 of the following:', 'a) Documented hysterectomy.', 'b) Documented bilateral salpingectomy.', 'c) Documented bilateral oophorectomy.', \"Note: Documentation can come from the study center personnel's: review of the subject's\", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'a) A postmenopausal state is defined as no menses for 12 months without an alternative', 'medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal', 'range may be used to confirm a postmenopausal state in women not using hormonal', 'contraception or hormonal replacement therapy (HRT). However, in the absence of 12', 'months of amenorrhea, a single FSH measurement is insufficient.', 'b) Females on HRT and whose menopausal status is in doubt will be required to use 1 of the', 'non-estrogen hormonal highly effective contraception methods if they wish to continue', 'their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation', 'of postmenopausal status before study enrollment.', 'Contraception Guidance', 'Female subjects of childbearing potential are eligible to participate if they agree to use a highly', 'effective method of contraception consistently and correctly as described in Table 8 below.', '69']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Table 8', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent', 'Failure rate of < 1% per year when used consistently and correctly.', 'Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulationb', 'Oral.', 'Intravaginal.', 'Transdermal.', 'Progestogen only hormonal contraception associated with inhibition of ovulation', 'Oral.', 'Injectable.', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen only hormonal contraception associated with inhibition of ovulationb', 'Intrauterine device (IUD).', 'Intrauterine hormone-releasing system (IUS).', 'Bilateral tubal occlusion.', 'Vasectomized partner', 'A vasectomized partner is a highly effective birth control method provided that the partner is the sole male sexual', 'partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method', 'of contraception should be used.', 'Sexual abstinence', 'Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual', 'intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence', 'needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the subject.', 'NOTES:', 'a', 'Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with', 'local regulations regarding the use of contraceptive methods for subjects participating in clinical studies.', 'b Hormonal contraception may be susceptible to interaction with the study treatment, which may reduce the efficacy', 'of the contraceptive method. In this case, 2 highly effective methods of contraception should be utilized during', 'the treatment period and for at least 30 days after the last dose of study treatment.', 'Pregnancy Testing:', 'WOCBP will only be included in the study after a confirmed negative urine pregnancy test', 'at Visit 2 (Baseline). The UPT must have a minimum sensitivity of 25 mIU beta human', 'chorionic gonadotropin.', 'Additional pregnancy testing will occur at times specified in the schedule of assessments', 'during the treatment period, at the Visit 6 (EOS), and as required locally.', '70']\n\n###\n\n", "completion": "END"}